This article is from: srnnews.com
Feb 24 (Reuters) – Fresenius Medical Care reported a sharp rise in fourth‑quarter operating income on Tuesday, helped by accelerating cost savings and favourable reimbursement effects.
The dialysis provider’s operating income excluding special items jumped 44% to 705 million euros ($830 million), beating analysts’ expectations for 633 million euros.
“We remain steadfast in our commitment to further improve profitability, while investing in our future and overcoming regulatory headwinds,” CEO Helen Giza said in a statement, adding the company was entering the next phase of its “FME Reignite” strategy.
The German dialysis group is undergoing a major overhaul under Giza, focused on margin recovery, cost discipline and portfolio simplification after its deconsolidation from former parent Fresenius in 2023.
Although fourth-quarter revenue, at 5.07 billion euros, came in broadly in line with market expectations, the strong profit performance suggests the company’s efficiency measures are gaining traction, helping offset U.S. labour cost inflation and currency pressures.
($1 = 0.8497 euros)
(Reporting by Maria Rugamer in Gdansk, editing by Milla Nissi-Prussak)
Brought to you by www.srnnews.com
